[Glucocorticoid and Bone. Collagen cross-link abnormalities in glucocorticoid induced osteoporosis].

Abstract

Bone fragility is one of the side effects of glucocorticoid (GC) use, even at low doses. An increase in fracture risk due to GC administration occurs immediately after beginning treatment. A number of GC-mediated effects are responsible for bone fragility. We demonstrated that GC administration deteriorates lysyl oxidase mediated collagen crosslink formation acting as a determinant of bone material properties (Saito M, et al., Calcified Tissue Int, 88 ; 314-424, 2011) . We reviewed the mechanism of low bone material quality by GC administration.

• Authors: Mitsuru Saito, Keishi Marumo
• Journal: Clinical calcium (Clin Calcium) Vol. 24 Issue 9 Pg. 1351-9 (Sep 2014) ISSN: 0917-5857 [Print] Japan
• PMID: 25177008 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Bone Density Conservation Agents
• Glucocorticoids
• Collagen

Topics

• Animals
• Bone Density (drug effects)
• Bone Density Conservation Agents (therapeutic use)
• Bone and Bones (drug effects)
• Collagen (metabolism)
• Glucocorticoids (pharmacology)
• Humans
• Osteoporosis (chemically induced, drug therapy, metabolism)